-
Something wrong with this record ?
Intensity-modulated radiotherapy in the treatment of subhepatic carcinomas
J. Petera, L. Kasaová, P. Paluska, I. Sirák, J. Jansa, Z. Macingová, J. Dvorák, R. Soumarova,
Language English Country Greece
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
21661392
Knihovny.cz E-resources
- MeSH
- Radiotherapy Dosage MeSH
- Cholangiocarcinoma radiotherapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Gallbladder Neoplasms radiotherapy MeSH
- Bile Duct Neoplasms radiotherapy MeSH
- Radiotherapy, Intensity-Modulated methods MeSH
- Aged MeSH
- Bile Ducts, Intrahepatic MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND/AIMS: The aim of our study was to evaluate preliminary results of intensity modulated radiotherapy (IMRT) in patients with inoperable subhepatic tumors. METHODOLOGY: Thirteen patients with inoperable cholangiocarcinoma or gall bladder carcinoma were treated by biliary drainage and intensity modulated radiotherapy. In patients with tumors limited to the biliary duct only tumor stenosis was irradiated to the dose of 50-60 Gy. In patients with bulky extraductal tumors the dose was 50 Gy/25 fractions to the whole tumor and an integrated boost was used to raise the dose to the malignant stenosis to 60 Gy/25 fractions. RESULTS: Doses to organs at risk (duodenum, small intestine, liver) were in tolerable limits. In four patients transient fever occurred; one patient had duodenal bleeding that resolved after conservative treatment. Recurrent dilatation of the biliary tract was observed in 4 patients and was managed by exchange of the internal biliary drainage. Median survival was 10.4 months, 5 patients survived for more than one year following diagnosis. CONCLUSIONS: IMRT of inoperable extrahepatic biliary tract tumors allows application of high doses of radiation to the tumor with effective sparing of healthy tissues. The control of jaundice is good. In selected cases IMRT may prolong overall survival.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12027500
- 003
- CZ-PrNML
- 005
- 20120924221305.0
- 007
- ta
- 008
- 120817s2011 gr f 000 0#eng||
- 009
- AR
- 035 __
- $a (PubMed)21661392
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Petera, Jiří, $d 1959- $7 xx0000229 $u Department of Oncology and Radiotherapy, Charles University Medical School and University Hospital, Hradec Králové, Czech Republic. petera@fnhk.cz
- 245 10
- $a Intensity-modulated radiotherapy in the treatment of subhepatic carcinomas / $c J. Petera, L. Kasaová, P. Paluska, I. Sirák, J. Jansa, Z. Macingová, J. Dvorák, R. Soumarova,
- 520 9_
- $a BACKGROUND/AIMS: The aim of our study was to evaluate preliminary results of intensity modulated radiotherapy (IMRT) in patients with inoperable subhepatic tumors. METHODOLOGY: Thirteen patients with inoperable cholangiocarcinoma or gall bladder carcinoma were treated by biliary drainage and intensity modulated radiotherapy. In patients with tumors limited to the biliary duct only tumor stenosis was irradiated to the dose of 50-60 Gy. In patients with bulky extraductal tumors the dose was 50 Gy/25 fractions to the whole tumor and an integrated boost was used to raise the dose to the malignant stenosis to 60 Gy/25 fractions. RESULTS: Doses to organs at risk (duodenum, small intestine, liver) were in tolerable limits. In four patients transient fever occurred; one patient had duodenal bleeding that resolved after conservative treatment. Recurrent dilatation of the biliary tract was observed in 4 patients and was managed by exchange of the internal biliary drainage. Median survival was 10.4 months, 5 patients survived for more than one year following diagnosis. CONCLUSIONS: IMRT of inoperable extrahepatic biliary tract tumors allows application of high doses of radiation to the tumor with effective sparing of healthy tissues. The control of jaundice is good. In selected cases IMRT may prolong overall survival.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a nádory žlučových cest $x radioterapie $7 D001650
- 650 _2
- $a žlučové cesty intrahepatální $7 D001653
- 650 _2
- $a cholangiokarcinom $x radioterapie $7 D018281
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a nádory žlučníku $x radioterapie $7 D005706
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a celková dávka radioterapie $7 D011879
- 650 _2
- $a radioterapie s modulovanou intenzitou $x metody $7 D050397
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kasaová, Linda
- 700 1_
- $a Paluska, Petr
- 700 1_
- $a Sirák, Igor
- 700 1_
- $a Jansa, Jan
- 700 1_
- $a Macingová, Zuzana
- 700 1_
- $a Dvorák, Josef
- 700 1_
- $a Soumarová, Renata
- 773 0_
- $w MED00002025 $t Hepato-gastroenterology $x 0172-6390 $g Roč. 58, č. 106 (2011), s. 331-5
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21661392 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20120924221458 $b ABA008
- 999 __
- $a ok $b bmc $g 949542 $s 784846
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 58 $c 106 $d 331-5 $i 0172-6390 $m Hepato-gastroenterology $n Hepatogastroenterology $x MED00002025
- LZP __
- $a Pubmed-20120817/11/03